6,4′-Dihydroxy-7-methoxyflavanone inhibits osteoclast differentiation and function

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 5, 2013, Pages 796-801

  Im, Nam Kyung ^a   Choi, Je Yong ^b   Oh, Hyuncheol ^c   Kim, Youn Chul ^c   Jeong, Gil Saeng ^a  

^a Keimyung University   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Wonkwang University   (South Korea)

Author keywords

6,4 dihydroxy 7 methoxyflavanone; Bone resorption; C Fos; Mitogen activated protein kinase; Nuclear factor of activatied T cells, cytoplasmic, calcineurin dependent 1; Osteoclast

Indexed keywords

6,4' DIHYDROXY 7 METHOXYFLAVANONE; FLAVANOID; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN C FOS; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG; 6,4'-DIHYDROXY-7-METHOXYFLAVANONE; ACTIN; BONE DENSITY CONSERVATION AGENT; FLAVANONE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME INHIBITION; GROWTH INHIBITION; IN VITRO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; ANIMAL; BONE MARROW CELL; CELL CULTURE; CYTOLOGY; DRUG EFFECT; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PHYSIOLOGY; DRUG EFFECTS; DRUG THERAPY;

ACTINS; ANIMALS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; BONE MARROW CELLS; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; FLAVANONES; MACROPHAGES; MALE; MICE; MICE, INBRED ICR; MITOGEN-ACTIVATED PROTEIN KINASES; OSTEOCLASTS; RANK LIGAND;

EID: 84876899212     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00964     Document Type: Article

References (39)

1. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature, 423, 337-342 (2003).
2. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med., 191, 275-286 (2000).
3. Suda T, Kobayashi K, Jimi E, Udagawa N, Takahashi N. The molecular basis of osteoclast differentiation and activation. Novartis Found. Symp., 232, 235-247, discussion, 247-250 (2001).
4. Bharti AC, Takada Y, Shishodia S, Aggarwal BB. Evidence that receptor activator of nuclear factor (NF)-kappaB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappaB-independent and TRAF6-dependent mechanism. J. Biol. Chem., 279, 6065-6076 (2004).
5. Manna SK, Aggarwal BB. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappaB activation and gene expression. J. Immunol., 162, 2095-2102 (1999).
6. Gravallese EM, Galson DL, Goldring SR, Auron PE. The role of TNF-receptor family members and other TRAF-dependent receptors in bone resorption. Arthritis Res., 3, 6-12 (2001).
7. Darnay BG, Ni J, Moore PA, Aggarwal BB. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J. Biol. Chem., 274, 7724-7731 (1999).
8. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell, 3, 889-901 (2002).
9. Bonjour JP. Calcium and phosphate: a duet of ions playing for bone health. J. Am. Coll. Nutr., 30 (Suppl. 1), 438S-448S (2011).
10. Kagan R. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms. J. Womens Health (Larchmt), 21, 975-981 (2012).
11. Christenson ES, Jiang X, Kagan R, Schnatz P. Osteoporosis management in post-menopausal women. Minerva Ginecol., 64, 181-194 (2012).
12. Reinholz GG, Getz B, Pederson L, Sanders ES, Subramaniam M, Ingle JN, Spelsberg TC. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res., 60, 6001-6007 (2000).
13. Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst. Rev., 4, CD002010 (2012).
14. Seelig MS, Altura BM, Altura BT. Benefits and risks of sex hormone replacement in postmenopausal women. J. Am. Coll. Nutr., 23, 482S-496S (2004).
15. Hong JW, Nam W, Cha IH, Chung SW, Choi HS, Kim KM, Kim KJ, Rhee Y, Lim SK. Oral bisphosphonate-related osteonecrosis of the jaw: the first report in Asia. Osteoporosis International, 21, 847-853 (2010).
16. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab., 95, 1555-1565 (2010).
17. Shimizu K, Yamanaka M, Gyokusen M, Kaneko S, Tsutsui M, Sato J, Sato I, Sato M, Kondo R. Estrogen-like activity and prevention effect of bone loss in calcium deficient ovariectomized rats by the extract of Pleurotus eryngii. Phytother. Res., 20, 659-664 (2006).
18. Qiu SX, Dan C, Ding LS, Peng S, Chen SN, Farnsworth NR, Nolta J, Gross ML, Zhou P. A triterpene glycoside from black cohosh that inhibits osteoclastogenesis by modulating RANKL and TNFalpha signaling pathways. Chem. Biol., 14, 860-869 (2007).
19. An RB, Jeong GS, Kim YC. Flavonoids from the heartwood of Dalbergia odorifera and their protective effect on glutamate-induced oxidative injury in HT22 cells. Chem. Pharm. Bull., 56, 1722-1724 (2008).
20. Chan SC, Chang YS, Wang JP, Chen SC, Kuo SC. Three new flavonoids and antiallergic, anti-inflammatory constituents from the heartwood of Dalbergia odorifera. Planta Med., 64, 153-158 (1998).
21. Lee SH, Kim JY, Seo GS, Kim YC, Sohn DH. Isoliquiritigenin, from Dalbergia odorifera, up-regulates anti-inflammatory heme oxygenase-1 expression in RAW264.7 macrophages. Inflammation Res., 58, 257-262 (2009).
22. Islam MT. Secondary metabolites from nonhost plants affect the motility and viability of phytopathogenic Aphanomyces cochlioides zoospores. Zeitschrift fur Naturforschung. C. J. Biosci., 63, 233-240 (2008).
23. Chowdhury AR, Sharma S, Mandal S, Goswami A, Mukhopadhyay S, Majumder HK. Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I. Biochem. J., 366, 653-661 (2002).
24. Makena PS, Pierce SC, Chung KT, Sinclair SE. Comparative mutagenic effects of structurally similar flavonoids quercetin and taxifolin on tester strains Salmonella typhimurium TA102 and Escherichia coli WP-2 uvrA. Environ. Mol. Mutagen., 50, 451-459 (2009).
25. Kumagai T, Müller CI, Desmond JC, Imai Y, Heber D, Koeffler HP. Scutellaria baicalensis, a herbal medicine: anti-proliferative and apoptotic activity against acute lymphocytic leukemia, lymphoma and myeloma cell lines. Leuk. Res., 31, 523-530 (2007).
26. Pandey MK, Sandur SK, Sung B, Sethi G, Kunnumakkara AB, Aggarwal BB. Butein, a tetrahydroxychalcone, inhibits nuclear factor (NF)-kappaB and NF-kappaB-regulated gene expression through direct inhibition of IkappaBalpha kinase beta on cysteine 179 residue. J. Biol. Chem., 282, 17340-17350 (2007).
27. Ji G, Yang Q, Hao J, Guo L, Chen X, Hu J, Leng L, Jiang Z. Anti-inflammatory effect of genistein on non-alcoholic steatohepatitis rats induced by high fat diet and its potential mechanisms. Int. Immunopharmacol., 11, 762-768 (2011).
28. Lee JW, Kobayashi Y, Nakamichi Y, Udagawa N, Takahashi N, Im NK, Seo HJ, Jeon WB, Yonezawa T, Cha BY, Woo JT. Alisol-B, a novel phyto-steroid, suppresses the RANKL-induced osteoclast formation and prevents bone loss in mice. Biochem. Pharmacol., 80, 352-361 (2010).
29. Li X, Udagawa N, Takami M, Sato N, Kobayashi Y, Takahashi N. p38 Mitogen-activated protein kinase is crucially involved in osteoclast differentiation but not in cytokine production, phagocytosis, or dendritic cell differentiation of bone marrow macrophages. Endocrinology, 144, 4999-5005 (2003).
30. Sakamoto H, Sakai E, Fumimoto R, Yamaguchi Y, Fukuma Y, Nishishita K, Okamoto K, Tsukuba T. Deltamethrin inhibits osteoclast differentiation via regulation of heme oxygenase-1 and NFATc1. Toxicology in Vitro, 26, 817-822 (2012).
31. Cheng ZJ, Kuo SC, Chan SC, Ko FN, Teng CM. Antioxidant properties of butein isolated from Dalbergia odorifera. Biochim. Biophys. Acta, 1392, 291-299 (1998).
32. Li B, Lee DS, Jeong GS, Kim YC. Involvement of heme oxygenase-1 induction in the cytoprotective and immunomodulatory activities of 6,4′-dihydroxy- 7-methoxyflavanone in murine hippocampal and microglia cells. Eur. J. Pharmacol., 674, 153-162 (2012).
33. Kim MH, Ryu SY, Choi JS, Min YK, Kim SH. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts. J. Cell. Physiol., 221, 618-628 (2009).
34. Han KY, Yang D, Chang EJ, Lee Y, Huang H, Sung SH, Lee ZH, Kim YC, Kim HH. Inhibition of osteoclast differentiation and bone resorption by sauchinone. Biochem. Pharmacol., 74, 911-923 (2007).
35. Kim MH, Ryu SY, Bae MA, Choi JS, Min YK, Kim SH. Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis. Food and Chemical Toxicology, 46, 3375-3382 (2008).
36. Hasegawa S, Yonezawa T, Ahn JY, Cha BY, Teruya T, Takami M, Yagasaki K, Nagai K, Woo JT. Honokiol inhibits osteoclast differentiation and function in vitro. Biol. Pharm. Bull., 33, 487-492 (2010).
37. Tsuka N, Motokawa M, Kaku M, Kawata T, Fujita T, Ohtani J, Koseki H, Sunagawa H, Matsuda Y, Abedini S, Hayashi H, Tanne K. Fms-like tyrosine kinase (Flt)-4 signaling participates in osteoclast differentiation in osteopetrotic (op/op) mice. Biomed. Res., 30, 31-37 (2009).
38. Zou W, Teitelbaum SL. Integrins, growth factors, and the osteoclast cytoskeleton. Ann. N. Y. Acad. Sci., 1192, 27-31 (2010).
39. Marie JC, Saltel F, Escola JM, Jurdic P, Wild TF, Horvat B. Cell surface delivery of the measles virus nucleoprotein: a viral strategy to induce immunosuppression. J. Virol., 78, 11952-11961 (2004).